Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | NDAQ

Overview

Corporate Details

ISIN(s):: US36870W1009
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Coherus Oncology, Inc. Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.	United States of America	CHRS
COLLEGIUM PHARMACEUTICAL, INC Develops and commercializes abuse-deterrent medications for responsible chronic pain management.	United States of America	COLL
CollPlant Biotechnologies Ltd Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.	United States of America	CLGN
Compass Therapeutics, Inc. A clinical-stage oncology firm developing antibody therapies that engage the immune system.	United States of America	CMPX
Compugen Ltd. Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.	Israel	CGEN
COMPUGEN LTD AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.	United States of America	CGEN
Connect Biopharma Holdings Ltd Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.	United States of America	CNTB
Context Therapeutics Inc. Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.	United States of America	CNTX
Contineum Therapeutics, Inc. Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.	United States of America	CTNM
CORCEPT THERAPEUTICS INC Develops and commercializes cortisol-modulating drugs for severe disorders like Cushing's syndrome.	United States of America	CORT